Published in Int J Urol on April 22, 2008
Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol (2009) 3.24
Prediagnostic circulating sex hormones are not associated with mortality for men with prostate cancer. Eur Urol (2013) 1.51
Targeting 5α-reductase for prostate cancer prevention and treatment. Nat Rev Urol (2011) 1.06
Role of bacteria in oncogenesis. Clin Microbiol Rev (2010) 1.05
Red wine and component flavonoids inhibit UGT2B17 in vitro. Nutr J (2012) 0.93
Genome-wide association study identifies a new locus JMJD1C at 10q21 that may influence serum androgen levels in men. Hum Mol Genet (2012) 0.93
DNA damage response and prostate cancer: defects, regulation and therapeutic implications. Oncogene (2014) 0.90
Current topics and perspectives relating to hormone therapy for prostate cancer. Int J Clin Oncol (2008) 0.90
The hypothalamic-pituitary-gonadal axis and prostate cancer: implications for androgen deprivation therapy. World J Urol (2013) 0.84
Preoperative low serum testosterone is associated with high-grade prostate cancer and an increased Gleason score upgrading. Prostate Cancer Prostatic Dis (2015) 0.80
Development and External Validation of a Nomogram Predicting the Probability of Significant Gleason Sum Upgrading among Japanese Patients with Localized Prostate Cancer. Prostate Cancer (2010) 0.78
Circulating sex steroids and prostate cancer: introducing the time-dependency theory. World J Urol (2013) 0.78
Identifying New Candidate Genes and Chemicals Related to Prostate Cancer Using a Hybrid Network and Shortest Path Approach. Comput Math Methods Med (2015) 0.76
The role of 5-alpha reductase inhibitors in prostate pathophysiology: Is there an additional advantage to inhibition of type 1 isoenzyme? Can Urol Assoc J (2009) 0.76
Intratumoral steroidogenesis in castration-resistant prostate cancer: a target for therapy. Prostate Int (2014) 0.75
Preoperative Serum Sex Hormone-Binding Globulin Level Is an Independent Predictor of Biochemical Outcome After Radical Prostatectomy. Medicine (Baltimore) (2015) 0.75
Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat Genet (2002) 2.76
Tumor-associated zinc finger mutations in the CTCF transcription factor selectively alter tts DNA-binding specificity. Cancer Res (2002) 2.52
The clinical potential of pretreatment serum testosterone level to improve the efficiency of prostate cancer screening. Eur Urol (2006) 2.16
Efficacy of traditional and alternative sunitinib treatment schedules in Japanese patients with metastatic renal cell carcinoma. Int J Urol (2014) 2.02
A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk. Cancer Res (2005) 2.02
Impact of IGF-I and CYP19 gene polymorphisms on the survival of patients with metastatic prostate cancer. J Clin Oncol (2006) 1.68
Functional significance of aberrantly expressed microRNAs in prostate cancer. Int J Urol (2015) 1.67
Chromogranin a concentration as a serum marker to predict prognosis after endocrine therapy for prostate cancer. J Urol (2002) 1.63
Incidence of inguinal hernia after prostate surgery: open radical retropubic prostatectomy versus open simple prostatectomy versus transurethral resection of the prostate. Int J Urol (2009) 1.63
External validation of a nomogram predicting the probability of prostate cancer Gleason sum upgrading between biopsy and radical prostatectomy pathology among Japanese patients. Urology (2009) 1.62
Preoperative masked renal damage in Japanese patients with primary aldosteronism: identification of predictors for chronic kidney disease manifested after adrenalectomy. Int J Urol (2012) 1.61
Is overactive bladder a brain disease? The pathophysiological role of cerebral white matter in the elderly. Int J Urol (2013) 1.54
Alteration of intra-pancreatic target-organ specificity by abrogation of Aire in NOD mice. J Clin Invest (2006) 1.52
Treatment outcomes of sorafenib for first line or cytokinerefractory advanced renal cell carcinoma in Japanese patients. Int J Urol (2010) 1.50
Analysis of IDH1 and IDH2 mutations in Japanese glioma patients. Cancer Sci (2009) 1.48
Outcomes of shockwave lithotripsy for upper urinary-tract stones: a large-scale study at a single institution. J Endourol (2005) 1.47
Health-related quality of life after carbon-ion radiotherapy for prostate cancer: a 3-year prospective study. Int J Urol (2013) 1.41
A novel role of the C-terminus of b 0,+ AT in the ER-Golgi trafficking of the rBAT-b 0,+ AT heterodimeric amino acid transporter. Biochem J (2009) 1.41
Visceral fat accumulation is a risk factor for urinary stone. Int J Urol (2014) 1.41
Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade. J Urol (2008) 1.41
A combination of fludarabine, half-dose cyclophosphamide, and anti-thymocyte globulin is an effective conditioning regimen before allogeneic stem cell transplantation for aplastic anemia. Int J Hematol (2014) 1.40
Active surveillance criteria for prostate cancer: can they be applied to Japanese patients? Int J Urol (2011) 1.40
Therapeutic outcomes of neoadjuvant and concurrent androgen-deprivation therapy and intensity-modulated radiation therapy with gold marker implantation for intermediate-risk and high-risk prostate cancer. Int J Urol (2015) 1.39
Early effect of dutasteride added to alpha-1 blocker therapy for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia. Int J Urol (2014) 1.39
Restoration of miR-145 expression suppresses cell proliferation, migration and invasion in prostate cancer by targeting FSCN1. Int J Oncol (2011) 1.39
Case of bilateral and multifocal renal cell carcinoma associated with Birt-Hogg-Dubé syndrome. Int J Urol (2014) 1.38
The TFL1 homologue KSN is a regulator of continuous flowering in rose and strawberry. Plant J (2011) 1.37
Clinicopathologic characteristics of peripheral squamous cell carcinoma of the lung. Am J Surg Pathol (2003) 1.35
Tumor suppressive microRNAs (miR-222 and miR-31) regulate molecular pathways based on microRNA expression signature in prostate cancer. J Hum Genet (2012) 1.32
Biphasic Aire expression in early embryos and in medullary thymic epithelial cells before end-stage terminal differentiation. J Exp Med (2010) 1.27
Renal cell carcinoma with unusual metastasis to the gallbladder. J Hepatobiliary Pancreat Surg (2008) 1.26
Bcl6 controls granzyme B expression in effector CD8+ T cells. Eur J Immunol (2006) 1.24
Neuroendocrine differentiation in the progression of prostate cancer. Int J Urol (2009) 1.21
Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors. Cancer Sci (2008) 1.20
Tumor-suppressive microRNA-218 inhibits cancer cell migration and invasion via targeting of LASP1 in prostate cancer. Cancer Sci (2014) 1.19
Altered methylation of multiple genes in carcinogenesis of the prostate. Int J Cancer (2003) 1.18
Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer. Cancer Epidemiol Biomarkers Prev (2013) 1.17
Carbon-ion radiation therapy for prostate cancer. Int J Urol (2012) 1.13
A randomized trial comparing radical prostatectomy plus endocrine therapy versus external beam radiotherapy plus endocrine therapy for locally advanced prostate cancer: results at median follow-up of 102 months. Jpn J Clin Oncol (2006) 1.13
Development of a nomogram to predict probability of positive initial prostate biopsy among Japanese patients. Urology (2006) 1.13
Prospective evaluation of selection criteria for active surveillance in Japanese patients with stage T1cN0M0 prostate cancer. Jpn J Clin Oncol (2008) 1.06
Common sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Am J Hum Genet (2002) 1.05
Pretreatment serum testosterone level as a predictive factor of pathological stage in localized prostate cancer patients treated with radical prostatectomy. Eur Urol (2004) 1.03
Association of UGT2B7 and ABCB1 genotypes with morphine-induced adverse drug reactions in Japanese patients with cancer. Cancer Chemother Pharmacol (2010) 1.02
Genetic linkage of UGT1A7 and UGT1A9 polymorphisms to UGT1A1*6 is associated with reduced activity for SN-38 in Japanese patients with cancer. Cancer Chemother Pharmacol (2007) 1.02
Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy. J Urol (2004) 1.02
Improved prostate cancer detection using systematic 14-core biopsy for large prostate glands with normal digital rectal examination findings. Urology (2006) 1.02
Meningitis-retention syndrome: first case of urodynamic follow-up. Intern Med (2011) 1.01
Development of a new nomogram for predicting the probability of a positive initial prostate biopsy in Japanese patients with serum PSA levels less than 10 ng/mL. Int J Urol (2008) 1.01
Expression of regulator of G protein signalling protein 5 (RGS5) in the tumour vasculature of human renal cell carcinoma. J Pathol (2004) 1.00
Genetic polymorphisms of hormone-related genes and prostate cancer risk in the Japanese population. Anticancer Res (2004) 1.00
Implications of insulin-like growth factor-I for prostate cancer therapies. Int J Urol (2008) 0.99
FOXA1 promotes tumor progression in prostate cancer via the insulin-like growth factor binding protein 3 pathway. PLoS One (2012) 0.99